Navigation Links
eRT Completes Milestone 100th Thorough QT Study
Date:10/14/2008

Critical step in determining cardiac safety of new drugs

PHILADELPHIA, Oct. 14 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), announced today the completion of its 100th Thorough QT Study. QT has been identified as a crucial cardiac safety marker; specifically, the prolongation of QTc is a known surrogate for assessing the cardiac safety risk of a new drug. eRT conducts Thorough QT Studies as one of the centralized ECG services provided within its EXPeRT platform for Cardiac Safety.

According to the most recent regulatory guidance, from the FDA and the ICH E14 Step 5 adopted in October 2005, the development of most candidate drugs should include a QT study conducted with standardized and validated digital equipment, designated cardiologists, consistent measurement methodology and digital data collection, storage and submission in XML format.

eRT began performing Thorough QT/QTc E14 trials as early as 2002. "Since then, the pharma industry has grown to understand the necessity of this type of study to preserve cardiac safety and mitigate the repolarization effects of new drugs," said Jeffrey Litwin, M.D., and Chief Medical Officer. "We have now completed 100 such trials, working with sponsors of all sizes, to construct and conduct these studies in a scientifically valid manner, providing the scientific and operational expertise they need for this important aspect of drug development."

Dr. Michael McKelvey, president and chief executive officer, commented, "The Thorough QT Study often stands as the gateway to Phase III studies and has become a known and accepted part of the drug development process. Coupling our TQT expertise with our breadth and depth in the Phase III environment allows us to continue driving value for our sponsors, helping them reach final regulatory hurdles with robust, high quality cardiac safety data. It is the lack of this data that remains the most significant barrier to final drug approval,
'/>"/>

SOURCE eResearchTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neptune Technologies successfully completes $2.75 million private placement with 10% management participation
2. Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale
3. Facet Solutions Completes Facet Joint and Disc Replacement Study
4. SyntheMed Completes $4.0 Million Equity Placement
5. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
6. SAFC Pharma Completes Large-Scale API Manufacturing Expansion in Ireland
7. Novagali Pharma Completes a EUR15 Million Fund Raising
8. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
9. Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix
10. Roche completes acquisition of ARIUS
11. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce that ... an e-Journal and producer of Food Labs Conference ... for the co-location of Food Labs Conference to be held ... registration fee to attend the two-day Food Lab Conference, March ...
(Date:1/15/2014)... 2014 ­ RedBrick Health , a fast-growing leader ... announces that EmblemHealth , the New ... now providing the RedBrick Compass health assessment, combined with ... of its members. EmblemHealth is among the first health ...
(Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... 1, 2011 Nycomed US Inc. ("Nycomed US") today announced ... Executive Officer and member of the Board for what will ... of the acquisition of Nycomed A/S by Takeda Pharmaceuticals.   ... the newly created position of Chief Operating Officer, and John ...
... signals, for the first time, to assist in braking, ... to the thousands of car accidents that are caused ... technique that attaches electrodes to the scalp , the ... traffic sensors, could detect a driver,s intention to break ...
... Protein Therapeutics Association (PPTA) applauds the introduction of bipartisan ... ( H.R. 2672 ) and ( S. 1423 ), which ... patients with rare diseases by eliminating barriers to innovation. ... therapies are coping with a very rare disease for which ...
Cached Biology Technology:Nycomed US Inc. Names Brian A. Markison as Chief Executive Officer 2Nycomed US Inc. Names Brian A. Markison as Chief Executive Officer 3Put the brakes on using your brain power 2PPTA Praises Legislation That Protects the Treatment of Rare Diseases 2
(Date:4/17/2014)... In the most densely forested and most densely ... centuries of human needs, values and practices. Disturbances associated ... for agriculture and development, have set the stage for ... Service study reports. , The report Five anthropogenic ... needs in the Northern United States was ...
(Date:4/17/2014)... development of stem cell therapies to cure a variety ... cell populations based on cell surface markers. Researchers from ... that is highly expressed in a type of stem ... describe in an article in BioResearch Open Access ... publishers. The article is available free on the ...
(Date:4/17/2014)... A credit-card-sized anthrax detection cartridge developed at Sandia ... makes testing safer, easier, faster and cheaper. , ... is commonly found in soils all over the world ... both humans and animals. The bacteria can survive in ... B. anthracis may occur through skin contact, inhalation ...
Breaking Biology News(10 mins):Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... in the brain improves recovery from stroke when injected up ... could be used as an effective stroke drug. A study ... Biology shows that an injection of Granulocyte-Colony Stimulating Factor (G-CSF), ... of neurons and counteract neurone death, reduces the size of ...
... disorders that have led to an epidemic of obesity and ... at Penn State University that are due to be published ... the National Academy of Science and also in the PNAS ... The discovery expands the known taxonomic breadth of metabolic ...
... get a lot easier and cheaper thanks to the work ... , Syed Hashsham, an associate professor in the Department of ... is developing a portable, hand-held device capable of detecting up ... , "This device will give us the ability ...
Cached Biology News:Brain protein improves stroke symptoms in rats, even when injected after 3 days 2Dragonfly's metabolic disease provides clues about human obesity 2Dragonfly's metabolic disease provides clues about human obesity 3Dragonfly's metabolic disease provides clues about human obesity 4Dragonfly's metabolic disease provides clues about human obesity 5Professors to develop hand-held pathogen testing device 2
... 100% capped transcripts with the translation boosting ... of 100% capped (versus 40% to 80% ... in about 2 hours. mScript™ also features ... shown to be up to 50% more ...
Immunogen: Synthetic peptide: M(1) C V P R S G L I L S(11) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Immunogen: Recombinant full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Immunogen: Synthetic peptide derived from ... and bovine Math-2. Specificity: Specific ... Human Rat (positive controls: human U251 ... lysates and rat brain homogenates)Storage: Store ...
Biology Products: